Study aid only. Verify against current guidelines before clinical use.

All 1,600+ trial summaries

Trials · Thoracic Oncology · Lung NSCLC - perioperative

AEGEAN trial

Heymach JV et al, N Engl J Med, 2023, PMID: 37870974

Summarized and reviewed by Veli Bakalov, MD · Updated

Medical OncologyThoracic OncologyLung NSCLC - perioperative2024

At a glance

Perioperative durvalumab with neoadjuvant chemotherapy significantly improved EFS and pCR in resectable NSCLC, though follow-up is short and OS immature.

Population
Treatment-naive resectable stage II-IIIB (N2) NSCLC, N=802
Design
Randomized phase III trial
Arms
Durvalumab + platinum chemo, then adjuvant durvalumab vs placebo + platinum chemo, then placebo
Primary endpoint
EFS and pCR
Key result
12-mo EFS 73.4% vs 64.5%, HR 0.68, 95% CI 0.53-0.88, P=.004; pCR 17.2% vs 4.3%
Background
Randomized phase III AEGEAN trial, N=802, in resectable stage II–IIIB (N2) NSCLC, excluding EGFR/ALK alterations from the efficacy analysis. Patients were treatment-naive.
Interventions and follow up
Arm A: Durvalumab 1500 mg IV Q3W + platinum-based chemotherapy for 4 cycles (neoadjuvant) → surgery → durvalumab IV Q4W for 12 cycles (adjuvant)
Arm B: Placebo IV Q3W + platinum-based chemotherapy for 4 cycles (neoadjuvant) → surgery → placebo Q4W for 12 cycles (adjuvant)
Primary endpoint: EFS, pCR
mFollow up: 11.7 mo
Results
Definitive surgery: ~77% each group
R0 resection: 94.7% vs 91.3%
Completed 12 cycles adjuvant: 24.0% (durvalumab) vs 21.1% (placebo)
EFS: not reached vs not reached; 12-mo EFS 73.4% vs 64.5%, HR 0.68, 95% CI 0.53–0.88, P=.004
OS: not reported at interim analysis
ORR: 56.3% vs 38.0%
pCR: 17.2% vs 4.3%
Adverse events
Overall: Grade 3–4 adverse events 42.4% vs 43.2%
Immune-mediated: 23.7% vs 9.3%
Conclusions
Perioperative durvalumab with neoadjuvant chemotherapy significantly improved EFS and pCR in resectable NSCLC, with a safety profile consistent with the known effects of the individual agents.
Key Limitations
Short follow-up (11.7 mo) with immature OS; EGFR/ALK excluded from efficacy; relative contribution of neoadjuvant vs adjuvant durvalumab not isolated.
Clinical Context
Perioperative durvalumab + chemotherapy is FDA/EMA approved for resectable NSCLC, an established perioperative chemoimmunotherapy option per ASCO/ESMO.
References
Heymach JV et al, N Engl J Med, 2023, PMID: 37870974
Open in the interactive trials browser View source ↗
HemeOncBuddy Clinical Trials Pivotal trial summaries in hematology and oncology Browse 1,600+ summaries by disease, filter by area or search by drug. Open all trial summaries